Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study.
Colleoni, Marco Giobbie-Hurder, Anita Regan, Meredith M Thürlimann, Beat Mouridsen, Henning Mauriac, Louis Forbes, John F Paridaens, Robert Láng, István Smith, Ian
Colleoni, Marco
Giobbie-Hurder, Anita
Regan, Meredith M
Thürlimann, Beat
Mouridsen, Henning
Mauriac, Louis
Forbes, John F
Paridaens, Robert
Láng, István
Smith, Ian
Citations
Altmetric:
Abstract
Among postmenopausal women with endocrine-responsive breast cancer, the aromatase inhibitor letrozole, when compared with tamoxifen, has been shown to significantly improve disease-free survival (DFS) and time to distant recurrence (TDR). We investigated whether letrozole monotherapy prolonged overall survival (OS) compared with tamoxifen monotherapy.
Description
Date
2011-03-20
Publisher
Collections
Keywords
Type
Article
Citation
Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. 2011, 29 (9):1117-24 J. Clin. Oncol.